Compare iShares International Treasury Bond ETF (IGOV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs TransMedics Group Inc — how do they compare? iShares International Treasury Bond ETF trades at $39.71 (market cap $1.30B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 2.1× iShares International Treasury Bond ETF's market cap, and TransMedics Group Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and TransMedics Group Inc for 24 Days on average.
| IGOV | TMDX | |
|---|---|---|
Market Cap | $1.30B | $2.74B |
Volume | 693,740 | 949,331 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $150.42 |
52-Week Low | $39.65 | $61.99 |
Typical Hold Time | 92 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.67, down 0.08% with a bearish technical signal from moving averages, while oscillators are neutral. Key financial ratios are unavailable, limiting fundamental clarity. Recent news highlights rising global bond yields, which may impact interest rate-sensitive stocks.
The outlook is cautious due to missing financial data and bearish technicals. Risks include macroeconomic pressure from higher yields, while opportunities depend on future earnings visibility. Investors need updated financials to assess valuation and growth prospects accurately.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
